slight correction if I may - its aimed for Q2 FY21 - which starts next month...so we should expect regulator news (accept/reject) by end Dec20
Also, there is no problems in India pop affording the tests in cities + towns. Avg income for majority middle-high income there is already equal to MY, Taiwan, Sth Korea and almost equal to our lowest pay rates in Australia.
Also, the main thrust of large scale orders is still governmental dept+hospitals purchases (for the poorer communities that can't buy tests), armed forces, private hospitals (that charge an arm + leg), lots of charities that are filling in the gaps + as someone else pointed out earlier, plenty also of high to super high income folks. That still equals a potential market of hundreds of millions (for all the available competition to sell to).
AT1 Price at posting:
37.5¢ Sentiment: Buy Disclosure: Held
